Biotechnology - Pharmacyclics

Filter

Current filters:

Pharmacyclics

Popular Filters

Bristol-Myers Squibb, Pharmacyclics and Janssen team up to test Opdivo and Imbruvica combination

Bristol-Myers Squibb, Pharmacyclics and Janssen team up to test Opdivo and Imbruvica combination

13-10-2014

US drug major Bristol-Myers Squibb, US-based biopharma company Pharmacyclics and Janssen Research and…

BiotechnologyBristol-Myers SquibbEuropeImbruvicaJanssenOncologyOpdivoPharmacyclics

Servier and Pharmacyclics end collaboration on abexinostat pan-HDAC inhibitor compounds

Servier and Pharmacyclics end collaboration on abexinostat pan-HDAC inhibitor compounds

26-09-2014

French privately-held drugmaker Servier is to end its collaboration with Pharmacyclics in the development…

abexinostatBiotechnologyFranceOncologyPharmacyclicsResearchServier

ASCO 2014: latest news on lapatinib and trastuzumab, and ibrutinib

ASCO 2014: latest news on lapatinib and trastuzumab, and ibrutinib

01-06-2014

There was more important news on investigational oncology products presented at the 2014 Annual Meeting…

BiotechnologyGlaxoSmithKlineibrutinibJanssen BiotechJohnson & JohnsonLapatinibOncologyPharmacyclicsResearchtrastuzumab

Pharmacyclics seeks additional indication for Imbruvica in USA

Pharmacyclics seeks additional indication for Imbruvica in USA

08-04-2014

USA-based Pharmacyclics has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug…

BiotechnologyImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmacyclicsRegulationUSA

FDA acceptance of ibrutinib NDA triggers milestone for Pharmacyclics

30-08-2013

California, USA-based Pharmacyclics (Nasdaq: PCYC) said yesterday (August 29, 2013) that the US Food…

BiotechnologyibrutinibJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

US FDA grants "breakthrough" status for Janssen and Pharmacyclics ibrutinib

14-02-2013

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, says that…

BiotechnologyibrutinibJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

Pharmacyclics gets second $50 million milestone from Janssen

21-08-2012

California, USA-based Pharmacyclics (Nasdaq: PCYC) announced yesterday that the SPARK (MCL2001) clinical…

BiotechnologyFinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Back to top